Blue Torch Aims Low: Negative Medicare NCD Could Boost Business, It Says
This article was originally published in The Gray Sheet
Executive Summary
Blue Torch Medical paradoxically expects that a Medicare national non-coverage decision for its CaverMap diagnostic to assess a patient's risk of impotency after radical prostatectomy will lead to increased sales
You may also be interested in...
Blue Torch Medical Gets What It Asked For In CMS Non-Coverage Proposal
CMS proposed national non-coverage of Blue Torch Medical's CaverMap prostate nerve diagnostic - just as the company had hoped
Blue Torch Medical Gets What It Asked For In CMS Non-Coverage Proposal
CMS proposed national non-coverage of Blue Torch Medical's CaverMap prostate nerve diagnostic - just as the company had hoped
UroMed
Voluntary bankruptcy filing under Chapter 7 in Boston federal court, announced May 15, "will result in the complete liquidation of the company's assets," UroMed says. The firm, doing business under the name Alliant Medical Technologies, offers brachytherapy seeds and needles for prostate cancer, treatment planning software for brachytherapy and external beam radiation therapy, and the CaverMap surgical aid for prostate and colorectal cancer surgery. Revenues in 2001 reached $6.1 mil., up 41.6%. However, the firm was unable to commercialize its products successfully, generating an accumulated deficit of $117.2 mil. as of December 2001...